Summary: The completion of MAPS’ Capstone Challenge continues to spread through the media, highlighting the shift in acceptance of psychedelic therapy. The success of the $30 million fundraising effort to fund the final research required to seek U.S. Food and Drug Administration (FDA) approval of MDMA-assisted psychotherapy for PTSD represents the growing support for new and innovative mental health treatments. “Should psychedelics be legalized, the drugs will present both a transformative mental health treatment and a major industry,” explains Quartz.
Originally appearing here.
